文献速递神经核医学肿瘤 PET/CT

18F-DOPA PET/CT对脑肿瘤多学科决策的影响

18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-01-05

该前瞻性单中心临床试验纳入组织学确诊的胶质母细胞瘤或脑转移患者,在神经肿瘤多学科委员会讨论中比较加入18F-DOPA PET前后诊断与治疗计划的变化。结果显示,在怀疑复发患者中18F-DOPA PET显著改变诊断与治疗决策并提高诊断准确性,但在评估胶质母细胞瘤治疗后残留浸润时影响较低。

要点

  • 怀疑脑转移复发时,18F-DOPA PET使诊断改变39.0%、治疗计划改变17.1%。
  • 怀疑胶质母细胞瘤复发时,18F-DOPA PET使诊断与治疗计划改变均为33.3%。
  • 评估胶质母细胞瘤治疗后残留时,诊断改变仅5.7%、治疗计划改变3.8%。

核心结论

  • 18F-DOPA PET对怀疑胶质母细胞瘤或脑转移复发的患者管理有显著影响。
  • 18F-DOPA PET用于评估一线放化疗或二线贝伐珠单抗后胶质母细胞瘤残留浸润时影响较低。

研究设计与样本

  • 前瞻性单中心临床试验IMOTEP纳入组织学确诊的胶质母细胞瘤或脑转移患者。
  • 患者因临床怀疑复发或评估治疗后残留肿瘤浸润而纳入,均行多模态脑MRI和18F-DOPA PET。
  • 多学科神经肿瘤委员会先基于临床和MRI数据提出诊断与治疗计划,再结合包括18F-DOPA PET的全部影像结果提出第二次诊断与治疗计划。
  • 以3个月随访后获得的回顾性最终诊断作为参考标准。

主要发现

  • 共106例患者经多学科神经肿瘤委员会前瞻性评估。
  • 脑转移患者41例均有临床复发怀疑,加入18F-DOPA PET后诊断改变39.0%、治疗计划改变17.1%。
  • 怀疑复发胶质母细胞瘤患者12例,加入18F-DOPA PET后诊断和治疗计划改变均为33.3%。
  • 评估治疗后残留胶质母细胞瘤浸润患者53例,18F-DOPA PET仅带来5.7%(3/53)诊断改变和3.8%(2/53)治疗计划改变。
  • 98/106例患者获得最终参考诊断;在怀疑肿瘤复发患者中,加入18F-DOPA PET使脑转移的Youden指数从0.44升至0.53,胶质母细胞瘤从0.2升至1.0。

临床怎么用

  • 对怀疑胶质母细胞瘤或脑转移复发的患者,可考虑加做18F-DOPA PET以辅助多学科诊断与治疗决策。
  • 对一线放化疗或二线贝伐珠单抗后评估胶质母细胞瘤残留浸润的患者,18F-DOPA PET对决策影响有限。

局限性

  • 本研究为单中心临床试验。
  • 最终参考诊断仅在98/106例患者中获得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to assess the therapeutic impact and diagnostic accuracy of 18F-DOPA PET/CT in patients with glioblastoma or brain metastases. METHODS: Patients with histologically proven glioblastoma or brain metastases were prospectively included in this monocentric clinical trial (IMOTEP). Patients were included either due to a clinical suspicion of relapse or to assess residual tumor infiltration after treatment. Multimodality brain MRI and 18F-DOPA PET were performed. Patients' data were discussed during a Multidisciplinary Neuro-oncology Tumor Board (MNTB) meeting. The discussion was first based on clinical and MRI data, and an initial diagnosis and treatment plan were proposed. Secondly, a new discussion was conducted based on the overall imaging results, including 18F-DOPA PET. A second diagnosis and therapeutic plan were proposed. A retrospective and definitive diagnosis was obtained after a 3-month follow-up and considered as the reference standard. RESULTS: One hundred six cases were prospectively investigated by the MNTB. All patients with brain metastases (N = 41) had a clinical suspicion of recurrence. The addition of 18F-DOPA PET data changed the diagnosis and treatment plan in 39.0% and 17.1% of patients' cases, respectively. Concerning patients with a suspicion of recurrent glioblastoma (N = 12), the implementation of 18F-DOPA PET changed the diagnosis and treatment plan in 33.3% of cases. In patients evaluated to assess residual glioblastoma infiltration after treatment (N = 53), 18F-DOPA PET data had a lower impact with only 5.7% (3/53) of diagnostic changes and 3.8% (2/53) of therapeutic plan changes. The definitive reference diagnosis was available in 98/106 patients. For patients with tumor recurrence suspicion, the adjunction of 18F-DOPA PET increased the Younden's index from 0.44 to 0.53 in brain metastases and from 0.2 to 1.0 in glioblastoma, reflecting an increase in diagnostic accuracy. CONCLUSION: 18F-DOPA PET has a significant impact on the management of patients with a suspicion of brain tumor recurrence, either glioblastoma or brain metastases, but a low impact when used to evaluate the residual glioblastoma infiltration after a first-line radio-chemotherapy or second-line bevacizumab.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Humbert O, Bourg V, Mondot L, et al. 18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions. Eur J Nucl Med Mol Imaging. 2019. PMID: 30612162. doi:10.1007/s00259-018-4240-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。